NCT00310232 2024-04-02
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Ontario Clinical Oncology Group (OCOG)
Phase 3 Terminated
Clinical Trials
9 trialsNCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00246597 2011-05-19
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00083434 2011-04-27
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00083486 2011-04-27
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00189371 2005-09-19
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
AGO Study Group
Phase 3 Terminated